Settings where the use of radioimmunotherapy (RIT) is under evaluation in non-Hodgkin lymphoma (NHL).
Chemotherapy-refractory indolent and transformed NHL
Rituximab-refractory indolent and transformed NHL
Single agent initial follicular NHL therapy
Combination chemotherapy + RIT in upfront indolent NHL
Combination rituximab + RIT in upfront indolent NHL
Combination chemotherapy + RIT in upfront diffuse large B cell lymphoma
Combination chemotherapy + RIT in upfront mantle cell lymphoma
RIT + chemotherapy in autologous stem cell transplantation
Sign In or Create an Account